Evidence map›Paper›PMID 34031415›Full record

ArticleNature communications2021

Pancreatic cancer prognosis is predicted by an ATAC-array technology for assessing chromatin accessibility.

S Dhara, S Chhangawala, H Chintalapudi, G Askan, V Aveson, A L Massa, L Zhang, D Torres, A P Makohon-Moore, N Lecomte and 17 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. GSK3βGut · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 6 institutions in 2 countries.

S Dhara *Dartmouth Geisel School of Medicine and Norris Cotton Cancer Center, Hanover, NH, USA.
S Chhangawala *Weill Cornell Graduate School of Medical Sciences, New York, NY, USA.ORCID 0000-0001-9626-1034
H ChintalapudiDartmouth Geisel School of Medicine and Norris Cotton Cancer Center, Hanover, NH, USA.
G AskanDavid M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
V AvesonDavid M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
A L MassaDartmouth Geisel School of Medicine and Norris Cotton Cancer Center, Hanover, NH, USA.ORCID 0000-0002-5888-2910
L ZhangDavid M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
D TorresDartmouth Geisel School of Medicine and Norris Cotton Cancer Center, Hanover, NH, USA.
A P Makohon-MooreDavid M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-4781-3565
N LecomteDavid M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
J P MelchorDavid M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
J BermeoDavid M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
A CardenasDavid M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
S SinhaDavid M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
D GlassmanDavid M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-5376-6526
R NicolleProgramme Cartes d'Identité des Tumeurs, Ligue Nationale Contre Le Cancer, Paris, France.ORCID 0000-0001-8084-1173
R MoffittStony Brook University, Stony Brook, NY, USA.ORCID 0000-0003-2723-5902
K H YuDavid M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
S LeppanenAgilent Technologies Inc., Santa Clara, CA, USA.
S LadermanAgilent Technologies Inc., Santa Clara, CA, USA.
B CurryAgilent Technologies Inc., Santa Clara, CA, USA.
J GuiDartmouth Geisel School of Medicine and Norris Cotton Cancer Center, Hanover, NH, USA.
V P BalachandranDavid M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-2956-223X
C Iacobuzio-DonahueDavid M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-4672-3023
R ChandwaniWeill Cornell Medicine, New York, NY, USA.
C S LeslieComputational Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. cleslie@cbio.mskcc.org.ORCID 0000-0002-4571-5910
S D LeachDartmouth Geisel School of Medicine and Norris Cotton Cancer Center, Hanover, NH, USA. sdl@dartmouth.edu.
Memorial Sloan Kettering Cancer Center · USDartmouth College · USAgilent Technologies (United States) · USCornell University · USLa Ligue Contre le Cancer · FRStony Brook University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Steven D Leach · 1985 to 2026
$91.3M
Defining neoantigen immunodominance for antigen selection and biomarker discovery in human pancreatic cancer immunotherapyU01CA224175 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BALACHANDRAN, VINOD P, LEACH, STEVEN D · 2017 to 2021
$3.1M
Comprehensive genetic dissection of druggable KRAS targetsR01CA204228 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LEACH, STEVEN D · 2016 to 2020
$1.9M
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA023108NCI NIH HHS R01 CA204228NCI NIH HHS U01 CA224175
6 · The paper itself

Abstract

Unlike other malignancies, therapeutic options in pancreatic ductal adenocarcinoma (PDAC) are largely limited to cytotoxic chemotherapy without the benefit of molecular markers predicting response. Here we report tumor-cell-intrinsic chromatin accessibility patterns of treatment-naïve surgically resected PDAC tumors that were subsequently treated with (Gem)/Abraxane adjuvant chemotherapy. By ATAC-seq analyses of EpCAM

Indexed as

ChromatinBiomarkers, TumorCarcinoma, Pancreatic DuctalCell NucleusChromatin Immunoprecipitation SequencingHepatocyte Nuclear Factor 1-betaHigh-Throughput Nucleotide SequencingHumansKruppel-Like Transcription FactorsPancreatic NeoplasmsPrognosisTranscription FactorsTranscriptomeBiomarkers, TumorChromatinHepatocyte Nuclear Factor 1-betaHNF1B protein, humanKruppel-Like Transcription FactorsTranscription FactorsZKSCAN1 protein, human

Identifiers

PMID34031415
PMCPMC8144607
OpenAlexW3165522976

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.